Tirzepatide
Also known as: Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist that has shown even greater weight loss results than semaglutide in head-to-head trials.
How it works
Tirzepatide uniquely activates both GIP and GLP-1 receptors, providing dual-action appetite suppression, improved insulin sensitivity, and enhanced metabolic effects beyond what single-receptor agonists achieve.
Common uses
- Weight management (Zepbound)
- Type 2 diabetes (Mounjaro)
Side effects
- Nausea and vomiting
- Diarrhea or constipation
- Decreased appetite
- Injection site reactions
- Rare: pancreatitis
Key research
- SURMOUNT-1 showed up to 22.5% weight loss at highest dose
- SURPASS trials demonstrated superior A1C reduction vs semaglutide
Safety notes
- Same thyroid C-cell tumor boxed warning as semaglutide
- Relatively newer to market — long-term safety data still accumulating
Too many clinics, not enough clarity?
We don't sell peptides. Tell us your goals and we'll connect you with a vetted provider who can figure out what actually makes sense for you.
See what's right for youExplore other peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. One of the most well-studied peptides available.
BPC-157
A synthetic peptide derived from human gastric juice, studied primarily in animal models for its regenerative and anti-inflammatory properties. Not FDA-approved.
CJC-1295 / Ipamorelin
A commonly paired combination of growth hormone-releasing peptides used to stimulate natural GH production for anti-aging, body composition, and recovery.